Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly subcutaneous NNC0662-0419 dose-finding study in adults with type 2 diabetes in Japan
jRCT2031250828Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2026
- Modality
- Peptides
01
Overview
Trial of NNC0662-0419 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Change in glycated haemoglobin (HbA1c) at week 16, Change in glycated haemoglobin (HbA1c) at week 28 and 1 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
NNC0662-0419
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031250828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250828.